GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » EV-to-FCF

Genscript Biotech (HKSE:01548) EV-to-FCF : -4.19 (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genscript Biotech's Enterprise Value is HK$14,571 Mil. Genscript Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-3,480 Mil. Therefore, Genscript Biotech's EV-to-FCF for today is -4.19.

The historical rank and industry rank for Genscript Biotech's EV-to-FCF or its related term are showing as below:

HKSE:01548' s EV-to-FCF Range Over the Past 10 Years
Min: -632.81   Med: -13.73   Max: 187.78
Current: -3.89

During the past 10 years, the highest EV-to-FCF of Genscript Biotech was 187.78. The lowest was -632.81. And the median was -13.73.

HKSE:01548's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.305 vs HKSE:01548: -3.89

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Genscript Biotech's stock price is HK$12.42. Genscript Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.355. Therefore, Genscript Biotech's PE Ratio for today is At Loss.


Genscript Biotech EV-to-FCF Historical Data

The historical data trend for Genscript Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech EV-to-FCF Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.91 -7.77 -30.70 -18.46 -10.20

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.70 - -18.46 - -10.20

Competitive Comparison of Genscript Biotech's EV-to-FCF

For the Biotechnology subindustry, Genscript Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genscript Biotech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's EV-to-FCF falls into.



Genscript Biotech EV-to-FCF Calculation

Genscript Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=14571.339/-3479.878
=-4.19

Genscript Biotech's current Enterprise Value is HK$14,571 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-3,480 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genscript Biotech  (HKSE:01548) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Genscript Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.42/-0.355
=At Loss

Genscript Biotech's share price for today is HK$12.42.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.355.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Genscript Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genscript Biotech (HKSE:01548) Business Description

Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Genscript Biotech (HKSE:01548) Headlines

No Headlines